Vijaya Diagnostic Centre Limited (NSE: VIJAYA | BSE: 543350) – Strategic Acquisition of Arya Wellness Centre

Introduction

On 11 September 2026, Vijaya Diagnostic Centre Limited filed a press‑release with the NSE and BSE, announcing the execution of a Business Transfer Agreement (BTA) to acquire 100 % of Arya Wellness Centre, a B2C‑focused integrated diagnostic business in Guwahati, Assam.

Key Details of the Acquisition

• Target: Arya Wellness Centre (joint venture of NEMRIL & Hexagonal Research Pvt. Ltd.)
• Location: GS Road, Guwahati – the principal healthcare hub of North‑East India
• Consideration: ≈ ₹46 crore (slump‑sale basis)
• Valuation: 8–9 × FY26 IND‑AS EBITDA of the target
• Closing Timeline: Expected within ≈ 3 months, subject to customary conditions precedent
• Deal Structure: Business Transfer Agreement (BTA) – EPS accretive from day one

Financial Highlights of Arya Wellness Centre (FY26)

Metric	Amount
Revenue from operations	≈ ₹26 crore
Business mix	56 % Pathology, 44 % Radiology
IND‑AS EBITDA	₹5.6 crore
IND‑AS Adjusted PAT	₹2.5 crore
B2C contribution	> 85 % of revenue

Strategic Rationale

• Geographic expansion: First foothold in the North‑East, complementing existing presence in West Bengal and creating a platform for further regional growth.
• Business model fit: Arya Wellness Centre operates an “All Under One Roof” integrated diagnostics model, aligning with Vijaya’s B2C‑focused growth strategy.
• Operational synergies: Access to a fully equipped centre offering MRI, CT, ultrasound, mammography, X‑ray, pathology, interventional radiology, and histopathology.
• Revenue diversification: Adds a profitable, high‑margin B2C operation to Vijaya’s portfolio, enhancing overall earnings per share.

Management Commentary

• Suprita Reddy, MD & CEO – Emphasised the acquisition as a “milestone” that strengthens Vijaya’s high‑quality, integrated diagnostics network and provides a gateway to the North‑East market.
• Narasimha Raju K A, CFO – Highlighted disciplined capital allocation, the 8–9 × EBITDA valuation, and immediate EPS accretion. Stressed continued focus on both organic and inorganic growth opportunities.
• Siva Rama Raju Vegesna, COO – Outlined the plan for a seamless transition, retention of the experienced clinical team, and leveraging Vijaya’s operating expertise to expand across Assam and the broader region.

Regulatory Filing

• The announcement complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
• The press release was submitted to the Listing Departments of both NSE and BSE, with the accompanying digital signatures of the CFO.

Outlook & Risks

• Closing Conditions: Transaction remains subject to standard conditions precedent; any delay could affect the anticipated EPS accretion.
• Forward‑looking statements: The release contains forward‑looking remarks that are subject to risks including economic changes, tax law modifications, litigation, and labour relations, which could cause actual results to differ.

---

For further information, investors may contact Mr. Dhiren Gala, Head of Investor Relations & Corporate Development, at +91 90598 93206 or dhiren.g@vijayadiagnostic.in.